Dr. Nadia Haroun, PharmD | Research Director

Role & Expertise

Dr. Nadia Haroun is Research Director at Remy Peptides, where she leads editorial review across all research articles published on the site. Her work covers GLP-1 receptor agonists, triple-agonist compounds such as retatrutide, and the broader obesity drug pipeline. Her expertise spans peptide analytical chemistry, HPLC purity validation, and clinical trial data interpretation.

Every article published in the Research Library is reviewed under Dr. Haroun’s direction for factual accuracy, proper citation of peer-reviewed sources, and compliance with the site’s editorial policy.

Credentials

Doctor of Pharmacy (PharmD)
Specialization in metabolic pharmacology and peptide therapeutics
8+ years in pharmaceutical research and regulatory analysis
Editorial oversight of 50+ research articles at Remy Peptides

Coverage Areas

GLP-1 and multi-receptor agonist pharmacology
Obesity drug approval timelines and regulatory pathways
Peptide stability, storage, and analytical verification
UAE regulatory compliance (MoHAP Circular 17/2022)
Comparative efficacy data across the metabolic drug pipeline

Editorial Standards

Articles authored by Dr. Haroun follow the standards documented on the Research Standards page, including:

Primary sourcing from peer-reviewed journals (NEJM, Lancet, Diabetes Care)
Clinical trial data cited with ClinicalTrials.gov registration numbers
Regulatory status verified against FDA, EMA, and MoHAP databases
No therapeutic claims — all content framed for research context
Regular updates when new trial readouts or regulatory decisions are published

Published Articles

Related Pages

Editorial Team — the Remy Peptides editorial board
Editorial Policy — content creation and review process
Research Standards — verification and compliance framework
About Remy Peptides — company background and mission